Organogenesis Q3: revenue falls 70% as cost cuts fail to keep pace, and cash drops to $26.9M
Wound care sales fell 73% year on year and the company is now in a loss-making, cash-burning phase, while 2026 revenue guidance was narrowed toward a slower Q4 recovery.
The quarter in numbers
Organogenesis reported third-quarter 2026 net revenue of $45.5 million, down $105.0 million, or 70%, from $150.5 million a year earlier. Advanced Wound Care (AWC) accounted for $38.2 million, down 73%. Surgical & Sports Medicine contributed $7.3 million, down 19%.
The bottom line swung from profit to loss. The company reported a net loss of $29.6 million, or $(0.25) per share, against net income of $21.6 million, or $0.11 per share, in Q3 2025. Adjusted net loss was $29.3 million versus adjusted net income of $23.2 million. Adjusted EBITDA was a loss of $22.4 million versus income of $30.1 million, a $52.5 million deterioration. The operating loss was $29.5 million versus operating income of $20.7 million.
The nine-month picture is starker. Net product revenue was $124.5 million, down 63% from $338.0 million. The net loss was $179.1 million, or $(1.47) per share, versus a loss of $6.7 million, or $(0.12), a year earlier.
Subscribe to keep reading
$4.99 / month
- Every article, analysis and opinion piece on CompePharma and VigiEye
- One subscription for both sites, cancel any time
Already a subscriber? Enter your email below: we'll send you a sign-in link. No password needed.
Sources
- Organogenesis Holdings Inc.: quarterly results release (SEC filing) SEC EDGAR · 05 Nov 2026
Written by CompePharma's editorial system (AI-assisted, model claude-sonnet-5-5) strictly from the official material listed. Earnings analysis is based on the company's results release filed with the SEC, not on the earnings call. It can contain errors; check the sources. Not investment advice.
CorMedix Q3: Post-TDAPA DefenCath Reset Meets Heron Deal and a Suspended 2027 Outlook
Consolidated revenue of $54.5M beat the consensus the company cited, but DefenCath pricing, a $3.1M adjusted EBITDA and suspended 2027 guidance leave Heron and REZZAYO carrying the story.
Iambic's Q3: AI-platform deals double revenue, but the clinic drives the burn
Collaboration revenue rose to $11.4M and pro forma cash reached about $455M after the IPO, while R&D and G&A spending climbed as Iambic moves three oncology assets toward and into the clinic.
Alumis posts narrower Q3 loss as NDA nears, but a lupus miss narrows envudeucitinib's path
Lower R&D cut the quarterly net loss to $94.9M, with a psoriasis NDA still due in 4Q 2026 and cash guided into 4Q 2027, while the LUMUS Phase 2b missed in the overall population.